Chimerix to begin Phase III CMV programme
This article was originally published in Scrip
Executive Summary
Chimerix plans to begin a Phase III cytomegalovirus (CMV) programme later this year following positive results from a Phase II study evaluating CMX001 in preventing CMV disease in allogeneic haematopoietic stem cell transplant (HCT) recipients.